Sanofi's Phase 3 vYF yellow fever vaccine trial in children active, not recruitingNov 6Weekly roundup, 4 itemsbelumosudilcetirizine hydrochloride and pseudoephedrine hydrochloride
Syndax reports Q3 2026 results, 90% Revuforj revenue growth, CFO transitionNov 2Quarterly updaterevumenibSyndax Pharmaceuticals Inc
Incyte reports GVHD cream results; INCA033989 Phase 1 PK study stays activeOct 29Weekly roundup, 2 itemsbioavailability enhancerINCA033989
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Incyte's radiolabeled INCB161734 mass balance study active, not recruitingOct 16Weekly roundup, 4 itemsINCA33890INCB161734
Incyte registers Phase 2 FIGHT-214 trial of pemigatinib in cholangiocarcinomaOct 9Weekly roundup, 2 itemsIncyte CorporationpemigatinibUpdated
Incyte-backed trials: OSU tests pemigatinib cycling regimen; OHSU starts Opzelura pilot for PGAug 24Weekly roundup, 2 itemsIncyte Corporationpemigatinib
Karyopharm says myelofibrosis sNDA submission remains on track for AugustAug 13Quarterly updateKaryopharm Therapeutics Inc
Syndax reports 2Q26 revenue growth, details EGFR and menin inhibitor pipeline additionsAug 4Quarterly updaterevumenibSyndax Pharmaceuticals Inc
Incyte raises 2026 sales guidance, adds ten data readouts, closes Vega dealJul 28Quarterly updateIncyte Corporation
Merck registers Phase 2/3 trial of bomedemstat versus standard therapies in polycythemia veraJul 23Trial updateMerck & Co., Inc.
BMS trials post results across lung cancer, sarcoma, myelofibrosis; new stroke study opensJul 17Weekly roundup, 5 itemsBristol Myers Squibblisocabtagene maraleucel
Incyte-linked ruxolitinib trials post results; both MGH and UT Southwestern studies reportJul 9Weekly roundup, 2 itemsIncyte Corporationruxolitinib